ArticleCurrent oncology (Toronto, Ont.)2022

Long-Term Molecular Remission after Treatment with Imatinib in a Chronic Myeloid Leukemia Patient with Extreme Thrombocytosis Harboring Rare e14a3 (b3a3) BCR::ABL1 Transcript: A Case Report.

Xupai Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.